

Saving Coronary Artery: TAVR-related Coronary Obstruction



Wei-Hsian Yin (殷偉賢), MD, PhD, FES

Professor of Medicine, Heart Center,
Cheng Hsin General Hospital and
National Yang Ming University, Taipei, Taiwan




CHGH



Acute coronary obstruction TAVR – a well-known and feared complication

Displacement of the native calcified valve leaflet over the coronary ostium or by clot forming in the sinus of Valsalva (most common).




Other possible mechanisms include impingement of the coronary ostium by the valve scaffold, commissural post, or leaflets.

Acute coronary obstruction TAVR – a well-known and feared complication

Balloon occlusion test





Post-dilatation



Acute coronary obstruction TAVR – a well-known and feared complication

Coronary occlusion


Left main stenting



Acute coronary obstruction TAVR – a well-known and feared complication

Left main stenting

Final angiogram




ANATOMICAL RISK FACTORS ON CT


- **Coronary height $\leq 10\text{mm}$**
- **Sinus of Valsalva $< 30\text{mm}$**
- **Narrow Sino-tubular junction**
- **Aortic Valve-in-valve**

D


Shallow sinuses of Valsalva

Low coronary ostium height







- ### Anatomical
1. Sinotubular junction dimensions
 2. Sinus height
 3. Leaflet length and bulkiness
 4. Sinus of Valsalva width
 5. Coronary height




- ### Device and Procedural
1. Commissural tab orientation
 2. Sealing skirt height
 3. Valve implant depth



Yudi, M.B. et al. J Am Coll Cardiol. 2019;71(12):1360-78.






Higher implant will be problematic in pats w/ low coronary take-off !

Transcatheter Aortic Valve-in-Valve Implantation for Patients With Degenerative Surgical Bioprosthetic Valves



Externally mounted bioprosthesis carries a even higher risk of CO and DCO.


The St. Jude Medical Trifecta 23mm has bovine pericardial leaflets that are mounted externally to the stent frame and carries a higher risk of CO.



HOW TO PREVENT IT?

- **Careful pre-procedural image studies and planning.**
- **Performing contrast aortography during balloon aortic valvuloplasty (balloon occlusion test) to assess the patency of the coronary arteries.**
- **Use of a transcatheter valve that can be retrieved or repositioned after valve implantation, such as the CoreValve Evolut R (Medtronic) or Lotus Edge (Boston Scientific Corporation), in high-risk cases.**
- **Coronary protection.**

Coronary Protection to avoid coronary obstruction



ID Type
2 Vessel Le


Coronary High for LCA :11.0mm and RCA: 18.2mm

Value
18.2 mm

Coronary Protection to avoid coronary obstruction

23mm balloon for BAV


**26mm Sapien XT (underfilled 2c.c)
with coronary protection**




Coronary Protection to avoid coronary obstruction

Post-dilatation
with full volume

Final Angiogram



Delayed Coronary Obstruction (DCO) – a rare and deadly complication




Even the post-implant aortography or selective cannulation of both coronary arteries had confirmed a lack of obstruction.....

**Coronary obstruction may occur
after the patient has left the procedure suite.**

Delayed Coronary Obstruction After Transcatheter Aortic Valve Replacement

FIGURE 3 Kaplan-Meier Curve of All-Cause Death After DCO

(J Am Coll Cardiol 2018;71:1513-24)



The in-hospital death rate was 50% (n = 19). The median follow-up of the survivors following delayed coronary obstruction (DCO) was 375 days (interquartile range: 35 to 1,026 days), and no case of stent thrombosis or death occurred in any patient who survived to hospital discharge. One patient underwent target-vessel revascularization during the follow-up period.

CENTRAL ILLUSTRATION Etiology and Risk Factors for Delayed Coronary Obstruction

Delayed Coronary Obstruction

0-7 Days

>7 Days

Early

Late

Etiology

Etiology

Continuing Expansion
Dissection
Hematoma

Thrombus
Fibrosis
Endothelialization

more likely to present with cardiac arrest or STEMI

more likely to present with stable or unstable angina

Anatomical Risk Factors

Procedural Factors

Procedural Factors

Pharmacological Factors

Narrow SOV
Low Coronary Height
Excessive Calcification

Valve-in-Valve
Device Position

Valve-in-Valve



Antiplatelet
Anticoagulation

Calcium

Low Coronary Height

Valve-in-Valve

Thrombus




— Definite — Probable — Possible


Case 1 Presentation (2)

F84 w/ HF


ANNULUS




SOV DIAMETER




LVOT



ASCENDING AORTA




Case 1 Presentation (3)



DCO Case


F 84, presented
with heart failure
and effort angina

After stenting for
LAD, TAVI was
done.




DCO Case

Started at 2-4mm




DCO Case

Releasing




DCO Case

End-up at 4mm




DCO Case

Final angiogram
at the end of
TAVI




DCO Case

30 minutes after TAVI, cardiogenic shock and then cardiac arrest developed. An angiogram was done.




DCO Case

Emergency PCI
was attempted,
but failed.



DCO Case


Emergency CABG
and reposition of
the CoreValve
manually was
done with
success.



Case 2 Presentation (1)

▫LCSJ, 90 years old female

**Annulus
26mm**



Distance: 31.3 mm x 22.2 mm
Area: 5.31 cm²
Avg. Diameter: 26.0 mm
Perimeter: 84.7 mm

FOV: 317.00 mm
100 kV
1276 mA
Tilt: 0.00
LAO 90: CAU 40
No: 1

P

1mm/div w:100

**RCA
17.6mm**

17.6 mm

R

**LCA
13.4mm**




13.4 mm

FOV: 317.00 mm
100 kV

Case 2

Presentation (2)

2016/04/19 TAVR with
a 29mm Edwards Sapien XT




Case 2 Presentation (3)

2016/12/08, the patient was asymptomatic, but a follow-up MSCT showed new tissue growth near the ostium of LM





Case 2 Presentation (4)

The patient declined PCI.




Case 2 Presentation (5)


2018/05/17, the patient was admitted for CAG because of Progressive typical angina for one month.



Case 2 Presentation (6)

2018/05/18: Direct stenting for LM ostial stenosis with a 4.0x12mm DES and post-dil. with a 4.5mm NC balloon under IVUD guidance.





Case 2 Presentation (7)

Final angiogram and IVUS



Why is DCO important?

- ***It is less rare than we recognize!***
- The incidence of DCO may be higher than reported because **sudden cardiac death outside the hospital** may be the first manifestation and thus DCO may go undiagnosed **if no autopsy** is performed.
- Patients may **be relatively protected** from the symptoms of coronary obstruction if they've had a **prior coronary artery bypass graft**.
- As we move to lower-risk patients, there could be **a greater incidence** of delayed coronary obstruction occurring due to patients having **a longer life expectancy post-TAVR**.
- ***There is no easy preventive strategy.***

When should we consider it?

- When someone TAVR patient gets sick or when you're told someone has died, this is something you need to think about.
- When you finish a case and **left with not much sinus of Valsalva and most of the sinus has been obliterated**, you need to give some thought to this possibility.
- *We need to **have a lower threshold for imaging the coronary system post-TAVR!***


How to manage it?

TABLE 5 Delayed Coronary Obstruction Details

	Overall (N = 38)	Early (0-7 Days) (n = 24)	Late (>7 Days) (n = 14)
LM revascularization	35	21	14
PCI	26 (74.3)	17 (81.0)	9 (64.3)
Successful	21 (80.8)	14 (82.4)	7 (77.8)
Unsuccessful	5 (19.2)	3 (17.6)	2 (22.2)
CABG	6 (17.1) [†]	2 (9.5)	4 (28.6)
Not attempted	4 (11.4)	2 (9.5)	2 (14.3)
RCA revascularization	10	7	3
PCI	6 (60.0)	4 (57.1)	2 (66.7)
Successful	1 (16.7)	1 (25.0)	0 (0.0)
Unsuccessful	5 (83.3)	3 (75.0)	2 (100.0)
CABG	3 (30.0) [‡]	1 (14.3)	2 (66.7)
Not attempted	3 (30.0)	3 (42.9)	0 (0.0)
Outcome			
In-hospital death	19 (50.0)	15 (62.5) [§]	4 (28.6) [§]

Tips and techniques for CAG or PCI after CoreValve/Evolute R

- Use **aortography** to confirm ostia takeoff points.
- Engage the coronary ostium **coaxially through the middle of the frame cell**:
JL4 → JL3.5/4.5
- If there is difficulty with the frame cell that is directly coaxial to the ostium, use the frame cell to the **left or right, or above** the ostium.
- Attempt a **partial selection**, then **engage with the wire**.
- **Use an extension** when extra support is needed or when the distance between the frame and the coronary ostia is large — commonly with RCA.
- After PCI, **disengage the guide catheter from the ostium over the guidewire** prior to removing through the frame cell.



Chimney stenting







Illustration of the BASILICA Procedure

A catheter directs an electrified guidewire through the base of the left aortic cusp into a snare in the left ventricular outflow tract **(A)**. After snare retrieval **(B)**, the mid-shaft of the guidewire is electrified to lacerate the leaflet **(C)**. The leaflet splays after TAVR permitting coronary flow **(D)**.



The advantages of J-valve in coronary protection

1. Deploy the claspers and secure the leaflets
2. Deploy the valve in the frame of claspers.



The low frame design and the direct anchoring mechanism that grasping the native or surgical prosthetic leaflets (ViV) between three claspers and valve stent can prevent the valve tissue from protruding into the sinus of Valsalva, which would mitigate the risk of coronary obstruction and facilitate future coronary reaccess.

TAKE HOME MESSAGES

- **Acute coronary obstruction (ACO)** after TAVR is a well-known and feared complication.
- It can be prevented by careful pre-procedural image studies and **planning** and **coronary protection** if needed.
- **Delayed CO** following TAVR is a **rare** phenomenon that is associated with a **high** in-hospital mortality rate.
- Clinicians should be aware that **DCO can occur after the originally successful TAVR procedure** and **have a low threshold for performing coronary angiography when clinically suspected**.
- Future studies should explore prosthesis design or delivery options for patients undergoing TAVR to reduce the occurrence of iatrogenic coronary ostial obstruction.